Observational studyBMC medicine2026
Real-world serplulimab plus chemotherapy for extensive-stage small cell lung cancer in china: an external validation of ASTRUM-005 trial.
Observational study in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06748495 (Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer: the Multicenter ASTRUM-005R Study
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Beyond Tumor Biology: Integrating Host Physiological Reserve into Perioperative Esophageal Cancer Care.Annals of surgical oncology · 2026Article
- Real-world serplulimab plus chemotherapy for extensive-stage small cell lung cancer in china: an external validation of ASTRUM-005 trial.BMC medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundIn the randomized phase 3 ASTRUM-005 trial, adding serplulimab to chemotherapy improved survival in extensive-stage small cell lung cancer (ES-SCLC), but whether these results generalize to routine practice remains uncertain. To evaluate the real-world effectiveness and safety of first-line serplulimab plus chemotherapy in China and to benchmark outcomes against the pivotal trial using a matching-adjusted indirect comparison (MAIC).
methodsThis nationwide, observational study enrolled ES-SCLC patients treated with serplulimab and investigator-selected chemotherapy across 14 sites in China. For subsequent analyses, patients were grouped by alignment with the ASTRUM-005 trial regimen: an RCT-regimen cohort and a real-world regimen cohort. The primary endpoints were overall survival (OS) and real-world progression-free survival (rwPFS); secondary endpoints included objective response rate (ORR) and safety. The MAIC weighted eligible real-world patients to the aggregate baseline profile of the pivotal trial.
resultsAmong 635 patients, the median OS was 17.20 months (95% CI, 15.43-19.77) and the median rwPFS was 8.17 months (95% CI, 7.40-9.20). The ORR was 69.05%, with comparable efficacy observed between RCT-regimen and real-world cohorts. Poor performance status and liver metastases independently predicted higher mortality. In the MAIC, OS in the RCT-regimen cohort was comparable to the serplulimab arm of the pivotal ASTRUM-005 trial (weighted log-rank P = 0.784). Safety was manageable and consistent with known profiles.
conclusionsThis large-scale real-world study confirms the efficacy of serplulimab plus chemotherapy and tolerability in diverse ES-SCLC population, supporting the external validity and generalizability of the pivotal ASTRUM-005 trial results. CLINICAL
trial registrationClinicalTrials.gov (NCT06748495).
Indexed as
Identifiers
42458439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.